Intellia Thera CS (NTLA) Stock Price, Quote & News

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune dis...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 6200

Website: www.intelliatx.com

Address:

40 Erie Street, Suite 130, Cambridge, United States

rxptgh Aug. 25 at 3:25 PM

$NTLA added more

0 · Reply

sogenerous Aug. 25 at 3:10 PM

$NTLA beautiful chart like buying nasdaq chart in 2003

1 · Reply

APman Aug. 25 at 3:09 PM

$NTLA

0 · Reply

StockMarketGuru Aug. 25 at 3:03 PM

$PRME $NTLA $CRSP

0 · Reply

SalmanAziz Aug. 25 at 2:36 PM

$NTLA looks good on the reversal trend. That 14 bucks plus target is a lot closer than you think.

0 · Reply

TradeParrot Aug. 25 at 2:28 PM

$NTLA UTRX breakout retest perfect higher low printed risk defined under base aiming for 033 into week end ✅

0 · Reply

Morty752 Aug. 25 at 2:14 PM

$NTLA This is on the right path. We will see higher prices in near future.

0 · Reply

sogenerous Aug. 25 at 2:02 PM

$NTLA nice gap out of flag on insider buy news

0 · Reply

PorkchopSquats Aug. 25 at 1:44 PM

$NTLA

0 · Reply

APman Aug. 25 at 1:31 PM

$NTLA $PRME $CRSP $BEAM Roll on up, for the price is down. Come on in for the best in town.

0 · Reply

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Aug 7, 2025, 8:17 PM EDT - 17 days ago

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 7:30 AM EDT - 24 days ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2025, 7:30 AM EDT - 25 days ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 30, 2025, 11:07 AM EDT - 26 days ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE QURE RCKT

Jul 18, 2025, 8:00 AM EDT - 5 weeks ago

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Jun 15, 2025, 10:45 AM EDT - 2 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

May 29, 2025, 11:25 AM EDT - 3 months ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 20, 2025, 5:47 AM EDT - 3 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT VANI VERV

May 18, 2025, 7:25 AM EDT - 3 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 14, 2025, 1:57 PM EDT - 3 months ago

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

May 12, 2025, 9:07 AM EDT - 3 months ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 8, 2025, 11:37 AM EDT - 3 months ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:44 AM EDT - 4 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

May 1, 2025, 7:30 AM EDT - 4 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Apr 23, 2025, 9:50 AM EDT - 4 months ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 14, 2025, 10:58 AM EDT - 4 months ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 10, 2025, 10:40 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 9, 2025, 10:49 AM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 3, 2025, 1:03 PM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Apr 3, 2025, 7:30 AM EDT - 5 months ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Mar 28, 2025, 6:24 AM EDT - 5 months ago

Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication

Mar 26, 2025, 7:30 AM EDT - 5 months ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Mar 11, 2025, 5:43 PM EDT - 5 months ago

Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 10, 2025, 6:03 PM EDT - 5 months ago

Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)

Mar 6, 2025, 5:45 AM EST - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA

Mar 2, 2025, 9:30 AM EST - 6 months ago

Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress

Feb 27, 2025, 12:30 PM EST - 6 months ago

Intellia Therapeutics, Inc. (NTLA) Q4 2024 Earnings Call Transcript

rxptgh Aug. 25 at 3:25 PM

$NTLA added more

0 · Reply

sogenerous Aug. 25 at 3:10 PM

$NTLA beautiful chart like buying nasdaq chart in 2003

1 · Reply

APman Aug. 25 at 3:09 PM

$NTLA

0 · Reply

StockMarketGuru Aug. 25 at 3:03 PM

$PRME $NTLA $CRSP

0 · Reply

SalmanAziz Aug. 25 at 2:36 PM

$NTLA looks good on the reversal trend. That 14 bucks plus target is a lot closer than you think.

0 · Reply

TradeParrot Aug. 25 at 2:28 PM

$NTLA UTRX breakout retest perfect higher low printed risk defined under base aiming for 033 into week end ✅

0 · Reply

Morty752 Aug. 25 at 2:14 PM

$NTLA This is on the right path. We will see higher prices in near future.

0 · Reply

sogenerous Aug. 25 at 2:02 PM

$NTLA nice gap out of flag on insider buy news

0 · Reply

PorkchopSquats Aug. 25 at 1:44 PM

$NTLA

0 · Reply

APman Aug. 25 at 1:31 PM

$NTLA $PRME $CRSP $BEAM Roll on up, for the price is down. Come on in for the best in town.

0 · Reply

stu4 Aug. 25 at 12:42 PM

$NTLA Like every day….the wall of shorts brings it down Even Bob Barker from his grave knows !!!

0 · Reply

Jadek6 Aug. 25 at 11:51 AM

$NTLA @Einsamer ..suffering from the bag holder syndrome of NTLA !! Sad soul

0 · Reply

Dkll303 Aug. 25 at 10:17 AM

$NTLA Just joint today ..oh boy !!! By the way, pre market , a hedge got an $11 off , on 11,000 shares Look-Siee now , lol …already making money , it is RED from $11

0 · Reply

wrengler4 Aug. 25 at 9:46 AM

$NTLA BFD …Sir Barry did at $SRPT and he did at $SAVA Hahahah …along with Sanderson at $24.75 , he’s DEAD now , lucky for him he never saw his fcuk up !

0 · Reply

wrengler4 Aug. 25 at 9:44 AM

$NTLA ask Barry that at $SRPT or even at $SAVA He has a different take on that ! Lol

0 · Reply

burbs88 Aug. 25 at 4:35 AM

$NTLA

0 · Reply

Srwitt Aug. 25 at 4:21 AM

$NTLA insiders only buy to make money…

0 · Reply

Joby099 Aug. 25 at 1:53 AM

$NTLA

0 · Reply

RotationReport Aug. 25 at 1:10 AM

$NTLA first insider buy in a long time with a director dropping 1M last week BTW, is that a big fake breakdown of long time pre covid support?

0 · Reply

Jadek6 Aug. 24 at 10:22 PM

$CADL $NTLA $REPL good answer to the underperforming loser ! Including these stocks !

2 · Reply

Jadek6 Aug. 24 at 10:20 PM

$NTLA Ouch ! That’s calling a spade a spade !

0 · Reply

Jadek6 Aug. 24 at 10:19 PM

$NTLA you call the truth, of a 2 point range in NTLA, bitter shorts.? Or trolls ? Not a bright statement, rather naive. The shorts are running this sh-t show and you are on the receiving end !! Clean your face, another sh-t just hit the fan. Even SOFI , is doing better and they diluted shareholders just a week ago Better stop dwelling on what shorts are doing, cause they are winning here , as you lose! @Einsamer

1 · Reply

Market Cap	1.13B
Revenue (ttm)	57.88M
Net Income (ttm)	-519.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-896.72%
Debt to Equity Ratio	0.00

Volume	3,219,700
Avg Vol	4,719,144
Day's Range	N/A - N/A
Shares Out	107.35M
Stochastic %K	41%
Beta	2.31
Analysts	Strong Sell
Price Target	$34.38